Literature DB >> 21529401

Probable non-vector-borne transmission of Zika virus, Colorado, USA.

Brian D Foy1, Kevin C Kobylinski, Joy L Chilson Foy, Bradley J Blitvich, Amelia Travassos da Rosa, Andrew D Haddow, Robert S Lanciotti, Robert B Tesh.   

Abstract

Clinical and serologic evidence indicate that 2 American scientists contracted Zika virus infections while working in Senegal in 2008. One of the scientists transmitted this arbovirus to his wife after his return home. Direct contact is implicated as the transmission route, most likely as a sexually transmitted infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21529401      PMCID: PMC3321795          DOI: 10.3201/eid1705.101939

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Zika virus (ZIKV), a mosquito-transmitted flavivirus, has been isolated from sentinel monkeys, mosquitoes, and sick persons in Africa and Southeast Asia (,). Serologic surveys indicate that ZIKV infections can be relatively common among persons in southeastern Senegal and other areas of Africa, but that ZIKV-associated disease may be underreported or misdiagnosed. In 2007, a large outbreak of ZIKV infection occurred on Yap Island in the southwestern Pacific that infected ≈70% of the island’s inhabitants (), which highlighted this virus as an emerging pathogen. The purpose of this study was to investigate and report 3 unusual cases of arboviral disease that occurred in Colorado in 2008.

The Study

Two American scientists (patients 1 and 2) lived and worked in the village of Bandafassi in southeastern Senegal in August 2008 while performing a mosquito-sampling project in surrounding villages. Patients 1 and 2 were men (36 and 27 years of age, respectively), and both had received the yellow fever 17D vaccine before their travel to Senegal. During their project, both patients reported being bitten often by wild Aedes spp. mosquitoes in the evenings while they worked. Patients 1 and 2 left Bandafassi on August 21, stayed in Dakar for 2 days, and then returned to their homes in northern Colorado on August 24. Both patients became ill 6–9 days after their return. Symptoms in patient 1 began on August 30 and consisted of swollen ankles, a maculopapular rash on his torso, and extreme fatigue and headache, but no fever was recorded. On August 31, he experienced the same symptoms and light-headedness and chills, wrist and ankle arthalgia, and symptoms of prostatitis (perineal pain and mild dysuria). However, he remained afebrile. Fatigue and rash decreased on September 1; only residual wrist arthralgia, headache, and prostatic symptoms persisted. On September 2, two aphthous ulcers appeared on his lip. On September 3, he and his wife observed signs of hematospermia (red–brown fluid in his ejaculate) that lasted until September 7. Patient 2 experienced his symptoms during August 29–September 1, which included a maculopapular rash on his torso, extreme fatigue, headache, and swelling and arthralgia in his wrists, knees, and ankles. However, symptoms of prostatitis or hematospermia did not devlop. Acute-phase blood samples were obtained from both patients on September 2. In patient 3 (a nurse and the wife of patient 1) similar clinical symptoms developed on September 3, including malaise, chills, extreme headache, photophobia, and muscle pain that continued through September 6. She did not have detectable fever. On September 7, a maculopapular rash developed on her torso (Figure) that expanded to her neck and thighs on the following day, and an aphthous ulcer developed on her inside lip. On September 8, arthralgia in her wrists and thumbs and conjunctivitis developed. Her acute symptoms waned over the next several days. Patient 3 had an acute-phase blood sample drawn on September 8. On September 11, she visited her primary care physician, who performed a complete blood count test and studies of hepatic function; all results were within reference ranges. Patient 2 reported wrist arthralgia for 1 month after his acute illness, and patients 1 and 3 have had recurring wrist or thumb joint arthralgia since their acute illness. Convalescent-phase blood samples were drawn on September 22 from patients 1 and 2 and on September 26 from patient 3.
Figure

Maculopapular rash on patient 3 infected with Zika virus, Colorado, USA.

Maculopapular rash on patient 3 infected with Zika virus, Colorado, USA. Acute-phase and convalescent-phase paired serum specimens from the 3 patients were tested independently by several different laboratories. Results of virus isolation were negative for all samples when tested in Vero and Aedes albopictus mosquito (C6/36) cell cultures and by intracerebral inoculation of acute-phase serum of patient 3 into suckling mice. Likewise, reverse transcription–PCRs with 16 different sets of arbovirus-specific primers did not detect arboviral RNA in any of the samples. Serologic analyses (Table A1) of samples from patients 1 and 2 showed matching results. Hemagglutination inhibition antibody titers and virus neutralizing titers were highly elevated above background levels for ZIKV and yellow fever virus (YFV) compared with other viruses tested. These titers most often increased in the time between obtaining acute-phase and convalescent-phase serum samples. Complement fixation tests against ZIKV and YFV antigens confirmed these interpretations. Hemagglutination inhibition, complement fixation, and virus neutralizing titers against ZIKV alone developed only in the convalescent-phase sample of patient 3.
Table A1

Serologic results for 3 patients in whom symptoms of arboviral illness developed, northern Colorado, USA, 2008*

Serum sampleViruses/viral antigens tested
GETVCHIKVSINVZIKVDENV1DENV2DENV3DENV4YFVWNVUGSVSLEVTAHVJCVLACV
Hemagglutination inhibition test
Pt1a00NT5,1202,5606402,5602,5605,1202,5601,280NT0NTNT
Pt1c00NT5,1201,2803201,2801,2802,5601,2801,280NT0NTNT
Pt2a00NT1,280160803203201,280160160NT0NTNT
Pt2c00NT2,560160803203201,280160160NT0NTNT
Pt3a00NT00000000NT0NTNT
Pt3c
0
0
NT
320
0
0
0
0
0
0
0
NT
0
NT
NT
Plaque-reduction neutralization test
Pt1aNT<10<10 10,240 80 1,280 320160 >20,480 <10NT80<10NTNT
Pt1cNTNTNT >40,960 160230320320 >40,960 160NTNTNTNTNT
Pt2aNTNTNT 10,240 <20808040 5,120 NTNTNTNTNTNT
Pt2cNTNTNT 40,960 80160160160 20,480 80NTNTNTNTNT
Pt3aNTNTNT10<10<10<10<10<10<10NT<10NT<10<10
Pt3c
NT
NT
NT
1,280
<10
<10
<10
<10
<10
<10
NT
NT
NT
NT
NT
Complement fixation test
Pt1aNTNTNT64/8NTNTNTNT64/8NTNTNTNTNTNT
Pt1cNTNTNT128/32NTNTNTNT64/8NTNTNTNTNTNT
Pt2aNTNTNT16/8NTNTNTNT16/8NTNTNTNTNTNT
Pt2cNTNTNT32/32NTNTNTNT16/8NTNTNTNTNTNT
Pt3aNTNTNT0NTNTNTNT0NTNTNTNTNTNT
Pt3cNTNTNT16/8NTNTNTNT0NTNTNTNTNTNT

*Togaviridae: GETV, Getah virus; CHIKV, chikungunya virus; SINV, Sindbis virus; Flaviviridae: ZIK, Zika virus; DENV, dengue virus; YFV, yellow fever virus; WNV, West Nile virus; UGSV, Uganda S virus; SLEV, St. Louis encephalitis virus; Bunyaviridae: TAHV, Tahyna virus; JCV, Jamestown Canyon virus; LAC, La Crosse virus; pt1, 2, and 3, patients 1, 2, and 3, respectively; a and c, acute-phase and convalescent-phase serum samples, respectively; NT, not tested. Hemagglutination test, numbers are reciprocal of serum dilution inhibiting 4 units of antigen; 0 = negative reaction at a 1:20 dilution. Plaque-reduction neutralization test, numbers refer to neutralizing antibody titers with a 90% cutoff value: titers > positive control serum samples are indicated in boldface. Complement fixation tests, numbers refer to reciprocal of serum titer/reciprocal of antigen titer; 0, negative reaction at <8/<8.

Conclusions

Evidence suggests that patients 1 and 2 were infected with ZIKV, probably in southeastern Senegal, by bites from infected mosquitoes. The village of Bandafassi is located in a disease-endemic area where ZIKV has been isolated from humans, nonhuman primates, and mosquitoes (,). Serologic results suggest an anamnestic response to ZIKV infection, likely stemming from their vaccination with YFV. The time between infection and the onset of clinical manifestations can be inferred to be >9 days, given the patients’ travel history. Their clinical symptoms are consistent with reported symptoms of ZIKV-associated disease (,–). Exceptions are aphthous ulcers in patient 1 (also reported by patient 3), prostatitis, and hematospermia. Whether these exceptions are typical but unreported symptoms or clinical anomalies is not clear. Results also support ZIKV transmission from patient 1 to patient 3. Patient 3 had never traveled to Africa or Asia and had not left the United States since 2007. ZIKV has never been reported in the Western Hemisphere. Circumstantial evidence suggests direct person-to-person, possibly sexual, transmission of the virus. Temperatures and mosquito fauna on the northern Front Range in Colorado when transmission occurred do not match known mosquito transmission dynamics of ZIKV by tropical Aedes species. Patient 3 had ZIKV disease 9 days after the return of her husband from Senegal. However, the extrinsic incubation period of ZIKV in Ae. aegypti mosquitoes was >15 days at 22°C–26°C (). Area temperatures during the week of return of patient 1 fluctuated between 10°C and 31°C, only Ae. vexans mosquitoes of the subgenus Aedimorphus are commonly captured on the northern Colorado Front Range, and known tropical ZIKV vectors are mostly from the subgenus Stegomyia (). Mosquito sampling around the home of patients 1 and 3 at the time yielded only 7 Ae. vexans mosquitoes and 11 other mosquitoes of the Culex and Culiseta genera. Furthermore, patients 1 and 3 reported having vaginal sexual intercourse in the days after patient 1 returned home but before the onset of his clinical illness. It is reasonable to suspect that infected semen may have passed from patient 1 to patient 3 during coitus. Another possibility is that direct contact and exchange of other bodily fluids, such as saliva, could have resulted in ZIKV transmission, but illness did not develop in the 4 children of patients 1 and 3 during this time. To the best of our knowledge, human sexual transmission of an arbovirus has not been documented. However, Japanese encephalitis virus was discharged into the semen of experimentally infected boars and could infect female pigs by artificial insemination (). Furthermore, West Nile virus RNA and St. Louis encephalitis virus antigen have been detected in urine of humans (,), and viruria has occurred in hamsters infected with West Nile virus () and Modoc virus (). If sexual transmission could be verified in subsequent studies, this would have major implications toward the epidemiology of ZIKV and possibly other arthropod-borne flaviviruses.
  15 in total

1.  A simple technique for infection of mosquitoes with viruses; transmission of Zika virus.

Authors:  J P BOORMAN; J S PORTERFIELD
Journal:  Trans R Soc Trop Med Hyg       Date:  1956-05       Impact factor: 2.184

2.  [Disorder of spermatogenesis and viral discharge into semen in boars infected with Japanese encephalitis virus (author's transl)].

Authors:  A Habu; Y Murakami; A Ogasa; Y Fujisaki
Journal:  Uirusu       Date:  1977-06

3.  Laboratory infection with Zika virus after vaccination against yellow fever.

Authors:  A R Filipe; C M Martins; H Rocha
Journal:  Arch Gesamte Virusforsch       Date:  1973

4.  Persistent shedding of West Nile virus in urine of experimentally infected hamsters.

Authors:  Jessica H Tonry; Shu-Yuan Xiao; Marina Siirin; Hongli Chen; Amelia P A Travassos da Rosa; Robert B Tesh
Journal:  Am J Trop Med Hyg       Date:  2005-03       Impact factor: 2.345

5.  Zika virus outbreak on Yap Island, Federated States of Micronesia.

Authors:  Mark R Duffy; Tai-Ho Chen; W Thane Hancock; Ann M Powers; Jacob L Kool; Robert S Lanciotti; Moses Pretrick; Maria Marfel; Stacey Holzbauer; Christine Dubray; Laurent Guillaumot; Anne Griggs; Martin Bel; Amy J Lambert; Janeen Laven; Olga Kosoy; Amanda Panella; Brad J Biggerstaff; Marc Fischer; Edward B Hayes
Journal:  N Engl J Med       Date:  2009-06-11       Impact factor: 91.245

6.  One-step RT-PCR for detection of Zika virus.

Authors:  Oumar Faye; Ousmane Faye; Anne Dupressoir; Manfred Weidmann; Mady Ndiaye; Amadou Alpha Sall
Journal:  J Clin Virol       Date:  2008-07-31       Impact factor: 3.168

7.  Antigenuria in St. Louis encephalitis.

Authors:  J P Luby; F K Murphy; J N Gilliam; C Y Kang; R Frank
Journal:  Am J Trop Med Hyg       Date:  1980-03       Impact factor: 2.345

8.  Zika virus, a cause of fever in Central Java, Indonesia.

Authors:  J G Olson; T G Ksiazek
Journal:  Trans R Soc Trop Med Hyg       Date:  1981       Impact factor: 2.184

9.  Characterization of persistent Modoc viral infections in Syrian hamsters.

Authors:  J W Davis; J L Hardy
Journal:  Infect Immun       Date:  1974-08       Impact factor: 3.441

10.  Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007.

Authors:  Robert S Lanciotti; Olga L Kosoy; Janeen J Laven; Jason O Velez; Amy J Lambert; Alison J Johnson; Stephanie M Stanfield; Mark R Duffy
Journal:  Emerg Infect Dis       Date:  2008-08       Impact factor: 6.883

View more
  420 in total

Review 1.  Zika virus and the never-ending story of emerging pathogens and transfusion medicine.

Authors:  Giuseppe Marano; Simonetta Pupella; Stefania Vaglio; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2015-11-05       Impact factor: 3.443

2.  Case Reports: Prolonged Detection of Zika Virus RNA in Vaginal and Endocervical Samples from a Brazilian Woman, 2018.

Authors:  Taís E da Cruz; Raquel P Souza; Sandra M Pelloso; Fabrício Morelli; Tamy T Suehiro; Edilson Damke; Patrícia de S Bonfim-Mendonça; Vânia R S da Silva; Marcia E L Consolaro
Journal:  Am J Trop Med Hyg       Date:  2019-01       Impact factor: 2.345

3.  Mapping and Role of the CD8+ T Cell Response During Primary Zika Virus Infection in Mice.

Authors:  Annie Elong Ngono; Edward A Vizcarra; William W Tang; Nicholas Sheets; Yunichel Joo; Kenneth Kim; Matthew J Gorman; Michael S Diamond; Sujan Shresta
Journal:  Cell Host Microbe       Date:  2017-01-11       Impact factor: 21.023

4.  A direct-acting antiviral drug abrogates viremia in Zika virus-infected rhesus macaques.

Authors:  So-Yon Lim; Christa E Osuna; Katharine Best; Ray Taylor; Elsa Chen; Gyeol Yoon; Jessica L Kublin; Dane Schalk; Nancy Schultz-Darken; Saverio Capuano; David Safronetz; Ma Luo; Steve MacLennan; Amanda Mathis; Yarlagadda S Babu; William P Sheridan; Alan S Perelson; James B Whitney
Journal:  Sci Transl Med       Date:  2020-06-10       Impact factor: 17.956

5.  A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against Zika.

Authors:  Jesse H Erasmus; Amit P Khandhar; Jeff Guderian; Brian Granger; Jacob Archer; Michelle Archer; Emily Gage; Jasmine Fuerte-Stone; Elise Larson; Susan Lin; Ryan Kramer; Rhea N Coler; Christopher B Fox; Dan T Stinchcomb; Steven G Reed; Neal Van Hoeven
Journal:  Mol Ther       Date:  2018-08-02       Impact factor: 11.454

Review 6.  Vaccination strategies against Zika virus.

Authors:  Estefania Fernandez; Michael S Diamond
Journal:  Curr Opin Virol       Date:  2017-04-19       Impact factor: 7.090

7.  Zika viral dynamics and shedding in rhesus and cynomolgus macaques.

Authors:  Christa E Osuna; So-Yon Lim; Claire Deleage; Bryan D Griffin; Derek Stein; Lukas T Schroeder; Robert Were Omange; Katharine Best; Ma Luo; Peter T Hraber; Hanne Andersen-Elyard; Erwing Fabian Cardozo Ojeda; Scott Huang; Dana L Vanlandingham; Stephen Higgs; Alan S Perelson; Jacob D Estes; David Safronetz; Mark G Lewis; James B Whitney
Journal:  Nat Med       Date:  2016-10-03       Impact factor: 53.440

Review 8.  Zika virus - reigniting the TORCH.

Authors:  Carolyn B Coyne; Helen M Lazear
Journal:  Nat Rev Microbiol       Date:  2016-08-30       Impact factor: 60.633

9.  Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen.

Authors:  Miao Xu; Emily M Lee; Zhexing Wen; Yichen Cheng; Wei-Kai Huang; Xuyu Qian; Julia Tcw; Jennifer Kouznetsova; Sarah C Ogden; Christy Hammack; Fadi Jacob; Ha Nam Nguyen; Misha Itkin; Catherine Hanna; Paul Shinn; Chase Allen; Samuel G Michael; Anton Simeonov; Wenwei Huang; Kimberly M Christian; Alison Goate; Kristen J Brennand; Ruili Huang; Menghang Xia; Guo-Li Ming; Wei Zheng; Hongjun Song; Hengli Tang
Journal:  Nat Med       Date:  2016-08-29       Impact factor: 53.440

10.  JMX0207, a Niclosamide Derivative with Improved Pharmacokinetics, Suppresses Zika Virus Infection Both In Vitro and In Vivo.

Authors:  Zhong Li; Jimin Xu; Yuekun Lang; Xiaoyu Fan; Lili Kuo; Lianna D'Brant; Saiyang Hu; Subodh Kumar Samrat; Nicole Trudeau; Anil M Tharappel; Natasha Rugenstein; Cheri A Koetzner; Jing Zhang; Haiying Chen; Laura D Kramer; David Butler; Qing-Yu Zhang; Jia Zhou; Hongmin Li
Journal:  ACS Infect Dis       Date:  2020-09-21       Impact factor: 5.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.